TrialClinical cancer research : an official journal of the American Association for Cancer Research2026

Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.

Paul L Swiecicki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.